*Since tofacitinib at 5 mg twice daily failed to be statistically significant for radiographic progression, and due to the step-down procedure applied to primary efficacy end points, significance was not declared for the HAQ Disability Index (DI) score or remission (DAS28-Erythrocyte Sedimentation Rate (ESR) <2.6) for tofacitinib at 5 mg twice daily.

†For both groups versus placebo. 

ACR, American College of Rheumatology; bDMARD, biological DMARD; csDMARD, conventional synthetic DMARD; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IR, inadequate responder; MTX, methotrexate; PROs, patient reported outcomes; RA, rheumatoid arthritis; SHS, van der Heijde modification of the total Sharp Score; TNFi, tumour necrosis factor inhibitor.